858 Therapeutics, Inc.
1 additional officer or director
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 4 directorsboard
4 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 1
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 1
Financing history
- Jun 26, 2024Form D equity offering · $25.2M (form d sold) · 12 investorsFact Form D · “858 Therapeutics, Inc. filed Form D: $25,175,501 sold of $50,350,497, Pharmaceuticals”
Investors on record
- Versant Venture Management, LLC board only, Clare Ozawa (strongly supported) Inference sec.gov
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.No firm portfolio page lists this company, so no outcome is stated.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- James Veal Executive Officer sec.gov
- Katherine Bell-Mcguinn Executive Officer sec.gov
- Stafford Jeffrey Executive Officer/Director sec.gov
- Jane Huang Director Fact
- Monal Mehta Director Fact
Show all 6 officers and directors
- James Veal Executive Officer sec.gov
- Katherine Bell-Mcguinn Executive Officer sec.gov
- Stafford Jeffrey Executive Officer/Director sec.gov
- Jane Huang Director Fact
- Monal Mehta Director Fact
- ALI Behbahani Director Fact
Timeline
- Jul 11, 2024858 Therapeutics, Inc. filed Form D: $25,175,501 sold of $50,350,497, PharmaceuticalsForm D filed Fact Form D
Evidence
Every observation on this company
- Entity type: Corporation Jul 11, 2024 Fact Form D
- Form D industry group: Pharmaceuticals Jul 11, 2024 Fact Form D
- Amendment: false Jul 11, 2024 Fact Form D
- Revenue range (Form D): Decline to Disclose Jul 11, 2024 Fact Form D
- Incorporated: overFiveYears Jul 11, 2024 Fact Form D
- Jurisdiction: Delaware Jul 11, 2024 Fact Form D
- Amount sold (Form D): $25.2M Jul 11, 2024 Fact Form D
- Offering amount (Form D): $50.4M Jul 11, 2024 Fact Form D
- Exemptions: 06b Jul 11, 2024 Fact Form D
- First sale: 2024-06-26 Jul 11, 2024 Fact Form D
- Investors (Form D): 12 Jul 11, 2024 Fact Form D
- Minimum investment (Form D): 0 Jul 11, 2024 Fact Form D
- Securities offered: equity Jul 11, 2024 Fact Form D
- Office address: Jul 11, 2024 Fact Form D
Relationships across DFX
2 capital paths
858 Therapeutics, Inc. sits on 2 traced paths of capital across the graphs.
DFX traced 2 paths of capital through this record
Every record on each path, what it committed or lent, and as of when.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Derived from allocator disclosures, BDC schedules and SEC filings; confidence is the weakest hop.
Checking your plan…
Record history
- Form D filed2024-07-11source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.